Marijuana M&A boom awaits, in California and beyond February 8, 2021 AggregatedNews Mergers & Acquisitions 0 Comments Jazz Pharmaceuticals’ $7.2-billion purchase of GW Pharmaceuticals last week is the biggest tie-up yet for the cannabis industry. And it’s probably just the beginning. The blockbuster deal, which dwarfs Tilray Inc. and Aphria Inc.’s $3.8-billion merger as well as Constellation Brands… Read More→
Cannabis ETFs Spike on Jazz-GW Pharma Deal February 5, 2021 AggregatedNews Cannabis Investments 0 Comments Cannabis stocks have been the biggest winners to start 2021 buoyed by hopes of wider legalization and near-term decriminalization as well as the growing adoption of marijuana in more states. The recent comments from several prominent politicians regarding cannabis reform… Read More→
Reading the Tea Leaves: Looking at the History of Hemp and CBD to Predict the Future March 10, 2020 Justin Walsh Hemp Policy & Legal 0 Comments By Justin Walsh[1] It’s an exciting time to be in hemp and CBD! I have attended and spoken at several conferences over the last year. I have been in places as diverse as Seattle, Denver, Dallas, and Orlando. The products… Read More→
Capitalizing on Legal Hemp! April 1, 2019 Mark Goldfogel Hemp Industry News 0 Comments An Entrepreneur's Guide By Mark Goldfogel In December of 2018, the U.S. Government legalized hemp; joining China, France, Great Britain and most of the developed world in recognizing that rope is not dope. This ended a prohibition on hemp dating… Read More→
First FDA approved cannabis-based drug now available by prescription November 2, 2018 AggregatedNews Policy & Legal 0 Comments The first cannabis-derived medication approved by the Food and Drug Administration is now available by prescription in every state, according to its manufacturer. Epidiolex, manufactured by GW Pharmaceuticals, is intended to treat seizures associated with two rare and severe forms of… Read More→
The drug maker behind the first FDA-approved medication derived from marijuana has revealed how much it’ll cost August 9, 2018 AggregatedNews Policy & Legal 0 Comments A marijuana-derived drug that recently became the first of its kind to win federal approval is not going to be cheap. Called Epidiolex, the drug is designed to treat two rare forms of childhood epilepsy using a cannabis compound called… Read More→
The FDA Just Approved the First-Ever Cannabis Based Drug in the U.S. June 26, 2018 AggregatedNews Policy & Legal, Science and Technology 0 Comments The Food and Drug Administration (FDA) for the first time approved a drug directly derived from cannabis on Monday, Epidiolex, developed by the British GW Pharmaceuticals. Although several states have legalized the medical and recreational use of marijuana, the federal… Read More→
Don’t Expect Joints If the FDA Ever Approves Medical Marijuana May 8, 2018 AggregatedNews Policy & Legal 0 Comments While past marijuana opponents like John Boehner are coming around to legal weed, the Food and Drug Administration isn’t likely to recommend that Americans light up a joint anytime soon. That doesn’t mean that cannabis will never be sanctioned by… Read More→
Marijuana-Based Epilepsy Drug Could Hit The U.S. Market By Mid-2018 January 25, 2018 AggregatedNews Policy & Legal 0 Comments A new class of epilepsy medications based on an ingredient derived from marijuana could be available as soon as the second half of 2018 in the United States, pending Food and Drug Administration approval. Officials from GW Pharmaceuticals, the company that developed the… Read More→
The 7 Largest Marijuana Stocks All Have This Dubious Statistic in Common: These are some lofty valuations with little to show for it. March 28, 2017 AggregatedNews Cannabis Investments, News & Insights 0 Comments Seemingly nothing can stop the marijuana industry, or marijuana stocks, at the moment. Over the past couple of years, we've witnessed a number of major milestones for the cannabis industry. For example, in 2012, Colorado and Washington became the first… Read More→
DEA and Big Pharma: The Tangled Web of the Opioid Crisis October 10, 2016 Ralph Morgan Opinions, The Buck Stops Here 1 Comment By Ralph Morgan Cannabis Industry leaders and activists are seemingly the only two groups with a sense of urgency to find a reasonable alternative pain remedy to replace synthetic opioids. Pharmaceuticals are responsible for a death every 19 minutes. Big… Read More→
Big Pharma Seeks to Capitalize on Pain-Reducing Compound Derived From Cannabis August 24, 2016 AggregatedNews Science and Technology 0 Comments The medicinal properties of cannabidiol (better known as CBD), a compound found in the Cannabis sativa L. plant species, are quickly drawing the attention of scientists, plant-medicine lovers, dietary-supplement companies, venture capitalists, professional athletes and Big Pharma -- not to… Read More→